Simulations Plus Inc (SLP) Actualités

Simulations Plus to Participate in the BTIG Digital Health Forum

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence...

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

Funded collaboration will leverage current FDA partnership to include additional LAI technologies Simulations Plus, Inc. (Nasdaq: SLP...

Simulations Plus to Participate in the Stephens Annual Investment Conference

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations

Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions Simulations...

Form 8-K - Current report

Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results

Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance...

Form 4 - Statement of changes in beneficial ownership of securities